

## **cabozantinib (CABOMETYX)**

### **Diagnoses Considered for Coverage:**

- Advanced differentiated thyroid cancer (follicular, papillary, and Hurthle type)
- Advanced renal cell carcinoma (aRCC)
- Endometrial carcinoma
- Ewing's Sarcoma or Osteosarcoma
- Gastrointestinal Stromal Tumors (GIST)
- Hepatocellular Carcinoma (HCC)
- Non-Small Cell Lung Cancer (NSCLC)

### **Coverage Criteria:**

1. **For diagnosis of advanced renal cell carcinoma:**
  - One of the following:
    - Being used in combination with nivolumab (Opdivo), **or**
    - Being used as a single agent,**and**
  - Dose does not exceed 60 mg per day.
2. **For diagnosis of advanced hepatocellular carcinoma (HCC):**
  - Patient has disease progression despite prior treatment for HCC, **and**
  - Being used as single agent therapy, **and**
  - Dose does not exceed 60 mg per day.
3. **For diagnosis of non-small cell lung cancer (NSCLC):**
  - Being used for advanced, recurrent, refractory, or metastatic disease, **and**
  - Provider attestation of the presence of RET rearrangement genetic alteration, **and**
  - Being used as a single agent therapy, **and**
  - Dose does not exceed 60 mg per day.
4. **For Ewing's Sarcoma or Osteosarcoma:**
  - For second-line therapy, **and**
  - Being used as single-agent therapy, **and**
  - Dose does not exceed 60 mg per day.
5. **For diagnosis of Gastrointestinal Stromal Tumors (GIST):**
  - Being used as subsequent therapy after disease progression with all the following:
    - imatinib (Gleevec),

- sunitinib (Sutent) or Sprycel (dasatinib),
- regorafenib (Stivarga),
- ripretinib (Qinlock),

**and**

- Being used as single agent therapy, **and**
- Dose does not exceed 60 mg per day.

**6. For diagnosis of recurrent endometrial carcinoma:**

- Being used for second-line or subsequent therapy, **and**
- Being used as single agent therapy, **and**
- Dose does not exceed 60 mg per day.

**7. For diagnosis of advanced differentiated thyroid cancer (follicular, papillary, and Hurthle type):**

- Inadequate response, or intolerable side effect, or contraindication to Lenvima (lenvatinib) and/or Nexavar (sorafenib), **and**
- Being used as single agent therapy, **and**
- Dose does not exceed 60 mg per day.

**References:**

1. Prescribing Information. Cabometyx. Exelixis Inc. 2022
2. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Gastrointestinal Stromal Tumors (GISTs) v2.2022. Available at [www.nccn.org](http://www.nccn.org)
3. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Uterine Neoplasm v1.2022. Available at [www.nccn.org](http://www.nccn.org)
4. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Bone Cancer v2.2023. Available at [www.nccn.org](http://www.nccn.org)
5. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Non-small cell Lung Cancer v6.2022. Available at [www.nccn.org](http://www.nccn.org)

Effective Date: 02/28/2024